Developing a targeted treatment for Hailey Hailey Disease
Official title: Towards a targeted therapy for Hailey Hailey Disease
Funded at Johns Hopkins University · NIH-10885628 · Data updated 2026-11-12
This study is looking into Hailey Hailey Disease, a rare skin condition that causes painful blisters, to better understand how a specific gene affects skin health, with the hope of creating a new treatment that can help make life easier for those living with this condition.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $163,750 |
| NIH project number | 1R03TR005427-01A1 |
| Project ID | NIH-10885628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hailey Hailey Disease who experience recurrent skin blistering and related complications.
✕Less likely to help
Patients with other skin disorders or those who do not have Hailey Hailey Disease may not benefit from this research.
What this research studies
This research focuses on Hailey Hailey Disease (HHD), a rare skin disorder that causes painful blisters primarily in skin folds. The study aims to understand the genetic and biochemical mechanisms behind HHD, particularly the role of the ATP2C1 gene and its protein product, SPCA1, in maintaining calcium levels crucial for skin cell adhesion. By investigating these mechanisms, the research seeks to develop a targeted therapy that could improve the quality of life for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to a specific treatment for Hailey Hailey Disease, significantly reducing symptoms and improving patients' quality of life.
How similar studies have gone: While research on Hailey Hailey Disease is limited, similar genetic and targeted therapy approaches have shown promise in treating other genetic skin disorders.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Rao, Rajini — Johns Hopkins University
- Study coordinator: Rao, Rajini
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
-
Targeted therapy for splicing-factor mutant myeloid cancers
Aims to test a dual drug strategy targeting ATR and PARP pathways in adults with splicing-factor mutant acute myeloid leukemia or related myeloid diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.